Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of MLN0128, MLN0128 + MLN1117, weekly paclitaxel, or weekly paclitaxel + MLN0128 in advanced, recurrent, or persistent endometrial cancer
2014-005394-37Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapanisertib, serabelisib and paclitaxel in endometrial cancer (EC) (4 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: progression-free survival. Started Jun 2016; status: completed.
02
Drugs
sapanisertibserabelisibpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2014-005394-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005394-37.